REGULUS THER.COMPAR DL001
Regulus Therapeutics Inc. engages in the development of drugs designed to inhibit dysregulated microRNA targets for the benefit of patients with genetically based orphan diseases. The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target o… Read more
REGULUS THER.COMPAR DL001 (7RG0) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, REGULUS THER.COMPAR DL001 (7RG0) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
REGULUS THER.COMPAR DL001 - Net Assets Trend (None–None)
This chart illustrates how REGULUS THER.COMPAR DL001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for REGULUS THER.COMPAR DL001 (None–None)
The table below shows the annual net assets of REGULUS THER.COMPAR DL001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to REGULUS THER.COMPAR DL001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
REGULUS THER.COMPAR DL001 Competitors by Market Cap
The table below lists competitors of REGULUS THER.COMPAR DL001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ucap Cloud Information Technology Co Ltd
SHG:688228
|
$414.75 Million |
|
Healthcare Co Ltd
SHG:603313
|
$414.76 Million |
|
Westaim Corp
V:WED
|
$414.98 Million |
|
Ceepower Co Ltd
SHE:300062
|
$414.99 Million |
|
Energy Vault Holdings Inc
NYSE:NRGV
|
$414.16 Million |
|
Opko Health Inc
NASDAQ:OPK
|
$414.11 Million |
|
Grape King Bio Ltd
TW:1707
|
$413.97 Million |
|
PT Sarana Menara
JK:TOWR
|
$413.86 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in REGULUS THER.COMPAR DL001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares REGULUS THER.COMPAR DL001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently REGULUS THER.COMPAR DL001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares REGULUS THER.COMPAR DL001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| REGULUS THER.COMPAR DL001 (7RG0) | €- | N/A | N/A | $414.38 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |